| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
NAV26 targets the voltage-gated sodium channel Nav1.7. It is a selective Nav1.7 channel blocker. By blocking Nav1.7 channels, NAV26 inhibits the generation and propagation of action potentials in nociceptive neurons, thereby reducing pain signaling. The compound shows >85-fold selectivity for Nav1.7 over Nav1.5 and hERG channels, which is important for minimizing cardiac side effects. NAV26 reduces nociceptive behavior in rat models of pain.
|
|---|---|
| ln Vitro |
In vitro, NAV26 selectively blocks Nav1.7 channels with an IC50 of 0.37 μM. It exhibits >85-fold selectivity for Nav1.7 over Nav1.5 and hERG channels. The compound's activity has been characterized in electrophysiological assays using cells expressing Nav1.7 channels. Detailed in vitro data are available in the primary literature. NAV26 is a valuable tool for studying Nav1.7 function in pain signaling.
|
| ln Vivo |
In vivo, NAV26 reduces nociceptive behavior in rat models of pain. It is extensively used in pain research to investigate Nav1.7-mediated nociceptive signaling and validate analgesic targets. The compound supports the development of novel analgesics with higher specificity and fewer CNS side effects. Further in vivo studies are needed to fully characterize its efficacy and safety profile.
|
| Enzyme Assay |
In vitro electrophysiological assays for NAV26 typically use cells expressing human Nav1.7 channels (e.g., HEK-293 transfectants). Whole-cell patch-clamp recordings are performed to measure sodium currents. The compound is dissolved in DMSO and diluted in extracellular solution. Cells are treated with NAV26 at various concentrations (0.001-10 μM), and voltage-dependent sodium currents are measured. IC₅₀ values are calculated from dose-response curves. Selectivity is assessed against Nav1.5 and hERG channels. Controls include vehicle and known sodium channel blockers.
|
| Cell Assay |
For cell-based assays, cells expressing Nav1.7 channels are cultured in appropriate medium. Cells are seeded in multi-well plates and loaded with voltage-sensitive dyes. Cells are treated with NAV26 at various concentrations (0.001-10 μM), and sodium channel activity is measured using fluorescence-based or electrophysiological methods. Cell viability is assessed by standard assays. All treatments include vehicle controls and are performed in triplicate.
|
| Animal Protocol |
In vivo, NAV26 is typically administered to rodents via intraperitoneal (IP) or intravenous (IV) injection. For pain models (e.g., formalin test, CFA-induced inflammatory pain, neuropathic pain models), animals are dosed at various regimens (e.g., 1-10 mg/kg). Endpoints include nociceptive behavior assessment (paw withdrawal threshold, latency), and tissue collection for biomarker analysis. Blood samples are collected for pharmacokinetic analysis. All procedures follow institutional animal care guidelines.
|
| ADME/Pharmacokinetics |
NAV26 (compound 26, MW 434.41, C₂₂H₂₁F₃N₂O₄) is a selective Nav1.7 channel blocker. It is soluble in DMSO (43.44 mg/mL). It shows >85-fold selectivity for Nav1.7 over Nav1.5 and hERG. Detailed pharmacokinetic parameters are available from preclinical studies. The compound is typically stored at -20°C. It is for research purposes.
|
| Toxicity/Toxicokinetics |
NAV26 is for research use only and not intended for human therapeutic applications. Standard safety pharmacology and toxicology studies would be required for therapeutic development. The compound should be handled with standard laboratory safety precautions. Toxicity data are limited in publicly available sources.
|
| Additional Infomation |
NAV26 (compound 26) is a research-grade selective Nav1.7 channel blocker for studying pain and nociceptive signaling. Its primary applications include pain research, neuroscience, and drug discovery. The compound is not approved for clinical use. It is commercially available from various chemical suppliers for research purposes only. Its mechanism involves selective Nav1.7 channel blockade, reducing nociceptive signaling.
|
| Molecular Formula |
C22H21F3N2O4
|
|---|---|
| Molecular Weight |
434.41
|
| Exact Mass |
434.145
|
| CAS # |
1198160-14-3
|
| PubChem CID |
44540282
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
607.7±55.0 °C at 760 mmHg
|
| Flash Point |
321.3±31.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.571
|
| LogP |
1.67
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
645
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(OC1C=CC(=CC=1)CNC(C1C2C=CC=CC=2C(N1C1CCOCC1)=O)=O)(F)F
|
| InChi Key |
ICGMZCVSHDKQTE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H21F3N2O4/c23-22(24,25)31-16-7-5-14(6-8-16)13-26-20(28)19-17-3-1-2-4-18(17)21(29)27(19)15-9-11-30-12-10-15/h1-8,15,19H,9-13H2,(H,26,28)
|
| Chemical Name |
2-(oxan-4-yl)-3-oxo-N-[[4-(trifluoromethoxy)phenyl]methyl]-1H-isoindole-1-carboxamide
|
| Synonyms |
NAV 26; NAV-26; NAV26
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3020 mL | 11.5099 mL | 23.0197 mL | |
| 5 mM | 0.4604 mL | 2.3020 mL | 4.6039 mL | |
| 10 mM | 0.2302 mL | 1.1510 mL | 2.3020 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
